FDA approves Sun Pharma Ilumya for adults with active psoriatic arthritis
The FDA has approved Sun Pharma's Ilumya for adults with active psoriatic arthritis, expanding the IL-23 inhibitor beyond its established plaque psoriasis indication.
Ilumya (tildrakizumab-asmn) received a supplemental biologics licence approval for active psoriatic arthritis following Phase III INSPIRE-1 and INSPIRE-2 studies that met their primary ACR20 response endpoints at week 24.
The new indication extends the medicine's use to inflammatory joint disease while retaining healthcare professional administration, providing another approved IL-23-targeted treatment option for eligible adults in the United States.
Field | Content |
Article Type | Approvals |
Company | Sun Pharma |
Product | Ilumya |
Generic Name | Tildrakizumab-asmn |
Modality | Monoclonal antibody |
Mechanism of Action | Interleukin-23 inhibition |
Regulator | U.S. Food and Drug Administration |
Approval Type | Supplemental biologics licence approval |
Approval Announcement Date | 30 October 2026 |
New Indication | Active psoriatic arthritis |
Patient Population | Adults with active psoriatic arthritis |
Therapeutic Area | Rheumatology; immunology |
Previously Approved Indication | Plaque psoriasis |
Clinical Studies | INSPIRE-1; INSPIRE-2 |
Study Phase | Phase III |
Study Design | Placebo-controlled clinical studies |
Primary Endpoint | ACR20 response at week 24 |
Clinical Results | Both INSPIRE-1 and INSPIRE-2 met their primary ACR20 endpoints at week 24 |
Numerical ACR20 Response Rates | Not confirmed in supplied summary |
Administration | Administered by a healthcare professional |
Patient Self-Injection | Not described as a self-injection product |
Geographic Scope | United States |
What Happened | The FDA expanded Ilumya's approved indications to include adults with active psoriatic arthritis. |
Why It Matters | The decision provides an additional IL-23-targeted treatment option for inflammatory joint disease and broadens Ilumya's clinical use beyond plaque psoriasis. |
Clinical Evidence | Two Phase III placebo-controlled studies met their primary ACR20 response endpoints at week 24. |
Key Takeaway | Ilumya now has a distinct US psoriatic arthritis indication supported by positive Phase III clinical evidence. |
What to Watch | Prescribing information, clinical guideline positioning, payer coverage, rheumatologist adoption and long-term safety outcomes. |
Primary Source | Sun Pharma via PR Newswire |
Primary Source URL | https://www.prnewswire.com/news-releases/ilumya-tildrakizumab-asmn-approved-in-the-us-for-the-treatment-of-adults-with-active-psoriatic-arthritis-302924320.html |
Relevant Date | 30 October 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
댓글